Tempus

Contact for Pricing

Tempus leverages AI-enabled precision medicine to transform patient care by making clinical and molecular data accessible and useful.

How Tempus can help you:

Accelerate the discovery of novel targets.
Predict the effectiveness of treatments.
Identify potentially life-saving clinical trials.
Diagnose multiple diseases earlier.
Enable more informed treatment decisions for physicians.
Assist in the development of better drugs for pharmaceutical and biotech companies.
Help patients find optimal therapy options.

Why choose Tempus: Key features

World’s largest library of clinical and molecular data.
AI-enabled operating system for data accessibility and usefulness.
FDA Breakthrough Device Designation for HLA-LOH assay.
Advanced testing, clinical trial matching, and deep research data for healthcare improvements.
AI-enabled clinical assistant Tempus One for direct patient insights.

Who should choose Tempus:

Physicians seeking informed treatment decisions.
Pharmaceutical and biotech companies targeting drug development.
Patients looking for personalized therapy options.
Researchers requiring access to comprehensive clinical and molecular data.

About Tempus

Website

https://www.tempus.com

Release Date

March 2024

Pricing

Contact for Pricing

Related fields

Related News

Life Sciences Organizations Gain New Real-World Data Offering To Bring Precision Therapies And Diagnostics To Patients

PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Life sciences organizations can now tap into de-identified real-world data from one of the most comprehensive repositories of pathology images alongside corresponding clinical and genomic data to accelerate the next breakthroughs in personalized care. Following a successful year-long pilot, Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, today announced the availability of a real-world data offering on its Concentriq® platform. Pathology, the last major field of medicine to go digital, is driving a new wave of precision medicine. Each whole slide image contains billions of pixels that provide one of the most detailed and direct profiles of diseases like cancer. Life sciences organizations can augment clinical and genomic data with this new modality and leverage recent advancements in AI to unlock insights that guide the development of novel therapies and diagnostics. "It's an exciting time for the future of healthcare," said Ben Freiberg, Ph.D., Principal Informatics Systems Lead at Genentech. "Pathology is fundamental to our understanding of disease; yet it has been a missing piece of the puzzle when it comes to drug discovery and development. Proscia is leading the way in enabling life sciences organizations to tap into high-value pathology datasets as a key component of real-world data." The addition of the real-world data offering on Concentriq enables biopharmaceutical organizations to: Access ready-to-use sets of multimodal data aligned to drug pipelines. Proscia provides highly-relevant, de-identified cohorts from a diverse repository of over 10 million whole slide images enhanced with structured data from molecular tests, pathology reports, laboratory tests, and next-generation sequencing across therapeutic areas. Data is further enriched with quantification of hundreds to thousands of AI-computed features to help generate deeper insights.Seamlessly incorporate data into studies and AI model development. Biopharmaceutical organizations receive cohorts on Concentriq, the same AI-enabled platform that powers their pathology from biomarker discovery to clinical trial execution. Scientists can quickly leverage them in their workflows, unlock new insights from whole slide images with Proscia's precision medicine AI portfolio, and develop proprietary AI models, including precision diagnostics, with the platform's developer tools.Accelerate the delivery of precision diagnostics to a growing laboratory network. As Concentriq is also used by national laboratories and health systems, biopharmaceutical organizations can deploy their precision diagnostics on the platform to this growing network. In turn, these AI-enabled tests can be easily distributed into clinical practice to match patients with the best treatments. "Life sciences organizations are turning to real-world data and AI to answer their biggest questions and advance precision medicine from bench to bedside," said David West, Proscia's CEO. "The interplay among whole slide images, clinical and genomic data, and novel therapies and diagnostics will only grow stronger. Proscia is uniquely positioned at this intersection to help our customers deliver the next generation of patient care." To learn more about Proscia's real-world data offering, register for its upcoming webinar. "From Bedside to Bench and Back: How Digital Pathology Is Fueling Precision Medicine With Unprecedented Real-World Data" is taking place on October 30, 2024 at 11AM EDT. Related resources: [Overview] Proscia's real-world data offering[Blog] Introducing Proscia's Real-World Data Offering: Empowering Life Sciences to Advance Precision Medicine Pipelines About Proscia Proscia is a software company accelerating pathology's transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity's most challenging diseases, like cancer. 14 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia's solutions each day. The company has FDA 510(k) clearance and was the first to secure CE-IVDR certification to advance digital pathology primary diagnosis in the European Union. For more information, visit proscia.com, and follow Proscia on LinkedIn and X. Contact Sydney Fenkell Head Of Marketing Communications 215-816-3436 sydney@proscia.com Market News and Data brought to you by Benzinga APIs

Benzinga

Wed, 4 Sept, 2:15 PM UTC

Behind the Scenes of Tempus AI's Latest Options Trends - Tempus AI (NASDAQ:TEM)

Investors with a lot of money to spend have taken a bearish stance on Tempus AI TEM. And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEM, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 13 uncommon options trades for Tempus AI. This isn't normal. The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish. Out of all of the special options we uncovered, 5 are puts, for a total amount of $228,930, and 8 are calls, for a total amount of $291,702. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $70.0 for Tempus AI during the past quarter. Analyzing Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you track the liquidity and interest for Tempus AI's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $35.0 to $70.0 in the last 30 days. Tempus AI Option Volume And Open Interest Over Last 30 Days Significant Options Trades Detected: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume TEM PUT SWEEP BEARISH 09/06/24 $11.3 $10.6 $11.3 $65.00 $113.0K 110 116 TEM CALL SWEEP BULLISH 10/18/24 $20.0 $18.9 $18.9 $40.00 $54.8K 115 124 TEM CALL SWEEP BULLISH 10/18/24 $20.1 $18.1 $18.1 $40.00 $52.4K 115 89 TEM CALL TRADE BEARISH 10/18/24 $24.9 $24.3 $24.3 $35.00 $34.0K 22 67 TEM PUT SWEEP BEARISH 08/30/24 $2.35 $2.0 $2.35 $57.00 $32.6K 2 101 About Tempus AI Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. Tempus AI's Current Market Status Currently trading with a volume of 662,195, the TEM's price is up by 2.29%, now at $66.44. RSI readings suggest the stock is currently may be approaching overbought. Anticipated earnings release is in 83 days. Expert Opinions on Tempus AI In the last month, 3 experts released ratings on this stock with an average target price of $44.666666666666664. An analyst from JP Morgan persists with their Overweight rating on Tempus AI, maintaining a target price of $47. Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $40. An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $47. Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely. If you want to stay updated on the latest options trades for Tempus AI, Benzinga Pro gives you real-time options trades alerts. Market News and Data brought to you by Benzinga APIs

Benzinga

Mon, 26 Aug, 8:02 PM UTC

Tribun Health Partners With Ibex to Deliver Advanced AI Diagnostic Solutions

PARIS, France and MONTREAL, Québec, August 28, 2024 (Newswire.com) - Tribun Health, a leading provider of digital pathology solutions, today announced a strategic partnership with Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics. Through this collaboration, Ibex's suite of AI-powered diagnostic tools will be available from Tribun Health's award-winning CaloPix® Information Management System (IMS), bringing cutting-edge AI capabilities to healthcare providers worldwide. Under the terms of the agreement, Tribun Health will offer Ibex's product line, which supports multiple tissues including prostate, breast, and gastric, as part of the CaloPix® IMS platform. These AI solutions leverage advanced deep learning algorithms to assist physicians in detecting and diagnosing various types of cancer with improved accuracy and efficiency. The integration of Ibex's AI tools into Tribun Health's Best in KLAS CaloPix® IMS will enable pathologists to access these powerful diagnostic tools within their existing clinical workflows. Cases will be automatically sent to Ibex's AI and results will be accessible in CaloPix® to define intelligent case triage and slide review. This partnership addresses the growing demand for intelligent, AI-driven solutions that can enhance diagnostic precision, streamline patient care, and improve overall healthcare outcomes. "We are excited to partner with Ibex and bring their cutting-edge AI diagnostic solutions to our customers," said Jean-François Pomerol, CEO at Tribun Health. "This collaboration aligns with our commitment to delivering innovative technology that empowers healthcare providers and improves patient care. It illustrates the opportunities and impactful developments in terms of care thanks to AI that the digitization makes possible to embrace." "We are thrilled to collaborate with Tribun Health and leverage their expertise in healthcare IT deployment and workflow optimization," said Joseph Mossel, CEO at Ibex. "Together, we can deliver intelligent diagnostic solutions that integrate into existing clinical practices, driving better patient outcomes and improving the overall healthcare experience." The partnership between Tribun Health and Ibex represents a significant step forward in the adoption of AI-driven solutions in healthcare. By combining their respective strengths, the two companies aim to advance cancer diagnostics through the offering of their joint solution in Canada, the European Union, and the United States. The integration aligns with Tribun Health's overarching AI strategy built on three core pillars: proprietary algorithms optimized for workflow efficiency and diagnostic precision, strategic collaborations with AI leaders like Ibex, and a generic API enabling seamless integration of any third-party and customer-developed algorithms. This multifaceted approach ensures pathology laboratories have access to a comprehensive AI-powered ecosystem tailored to their unique needs.

Newswire.com

Wed, 28 Aug, 8:03 AM UTC

AI in Oncology Market Size is Projected to Reach USD 7.7 billion by 2034, Growth at CAGR 16.8% | Report by Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The global AI in oncology market (종양학 시장의 AI) is estimated to thrive at a CAGR of 16.8% from 2024 to 2034. Transparency Market Research projects that the overall sales revenue for AI in oncology is estimated to reach US$ 7.7 billion by the end of 2034. Leveraging real-world data from electronic health records and wearables, AI enables insights into patient outcomes, treatment effectiveness, and disease progression, enhancing clinical decision-making and research efforts. AI-powered virtual tumor boards facilitate multidisciplinary collaboration among healthcare professionals, enabling real-time discussion of complex cases, treatment planning, and knowledge sharing to improve patient care outcomes. AI-driven patient engagement platforms empower patients with personalized health information, treatment education, and support resources, fostering active participation in their care journey and adherence to treatment regimens. Integration of blockchain technology ensures secure and transparent management of patient data, enabling interoperability, data sharing, and compliance with privacy regulations, fostering trust and collaboration within the healthcare ecosystem. For More Details, Request for a Sample of this Research Report: https://www.transparencymarketresearch.com/ai-in-oncology-market.html AI algorithms analyze social determinants of health data to identify socio-economic factors influencing cancer outcomes, enabling targeted interventions and support services to address health disparities and improve health equity. Key Findings of the Market Report Lung cancer leads the AI in oncology market due to its high prevalence and the urgent need for accurate diagnostic solutions.Diagnosis is leading the AI in oncology market, with advanced algorithms enhancing early detection and accurate identification of cancerous conditions.Hospitals & clinics lead the AI in oncology market, driving adoption of AI-driven solutions for cancer diagnosis, treatment planning, and patient care. AI in Oncology Market Growth Drivers & Trends AI enables personalized treatment approaches based on individual patient characteristics, optimizing cancer therapy effectiveness and minimizing adverse effects.Advanced algorithms enhance the accuracy of medical imaging interpretation, aiding early cancer detection and treatment planning.AI accelerates drug discovery processes by analyzing vast datasets, identifying potential therapeutic targets, and optimizing drug development pipelines.AI-powered decision support systems assist healthcare professionals in making informed treatment decisions, improving patient outcomes and reducing healthcare costs.Integration of AI technologies with telemedicine platforms facilitates remote consultations, enabling access to specialized oncology care for patients in underserved regions. Global AI in Oncology Market (L'IA sur le marché de l'oncologie): Regional Profile North America, particularly the United States, leads the charge in AI-driven oncology solutions. With a robust healthcare infrastructure, extensive research facilities, and substantial investment in technology, North America fosters a thriving ecosystem for AI applications in cancer diagnosis, treatment, and research. Key players like Paige.AI and Tempus spearhead advancements, collaborating with leading healthcare institutions to pioneer groundbreaking solutions.Europe, renowned for its strong emphasis on healthcare innovation and research, sees significant adoption of AI in oncology. Countries like the United Kingdom, Germany, and France leverage AI technologies to enhance cancer care delivery, improve patient outcomes, and optimize healthcare resource utilization. Companies such as Ibex Medical Analytics and PathAI drive innovation, partnering with academic institutions and healthcare providers to deploy AI-powered solutions across the region.Asia Pacific, propelled by rapid technological advancements and growing healthcare investments, emerges as a key player in the global AI in Oncology market. Countries like China, Japan, and South Korea invest heavily in AI-driven cancer diagnostics and treatment, aiming to address the region's rising cancer burden. Collaborations between technology firms, healthcare organizations, and government agencies drive innovation, shaping the future of cancer care in Asia Pacific and beyond. For Complete Report Details, Request Sample Copy from Here- https://www.transparencymarketresearch.com/ai-in-oncology-market.html AI in Oncology Market: Competitive Landscape In the competitive landscape of the AI in oncology market, pioneering companies like Paige.AI, Tempus, and Ibex Medical Analytics lead the charge. These innovators harness artificial intelligence to revolutionize cancer diagnostics, treatment planning, and research. Established players such as IBM Watson Health and Google Health also compete, leveraging their technological expertise and vast datasets to develop AI-driven oncology solutions. Startups like PathAI and DeepMind Health disrupt the industry with novel approaches to analyzing medical imaging and genomic data. Collaboration between industry leaders, research institutions, and healthcare providers drives innovation, fostering a dynamic ecosystem focused on improving patient outcomes in oncology. Some prominent players are as follows: Paige.AITempusIbex Medical AnalyticsPathAIProscia Inc.DeepMindSOPHiA GENETICSEnliticPrognos HealthInspirata Inc. Product Portfolio Paige.AI pioneers AI-driven pathology solutions, revolutionizing cancer diagnostics and treatment planning. Their advanced platform harnesses machine learning to analyze vast amounts of pathology data, empowering clinicians with insights for more accurate and personalized patient care.Tempus utilizes AI and genomic data to revolutionize cancer care. Their platform enables data-driven precision medicine, offering insights for diagnosis, treatment, and research, ultimately improving patient outcomes and accelerating advancements in oncology.Ibex Medical Analytics specializes in AI-powered cancer diagnostics solutions. Their platform, powered by deep learning algorithms, enhances pathology workflows, providing accurate and efficient cancer detection to support healthcare professionals in making informed clinical decisions. AI in Oncology Market: Key Segments By Cancer Type Lung CancerBreast CancerColorectal CancerOvarian CancerOthers By Application DiagnosisTreatment SelectionDrug DiscoveryPatient Management and Care By End User Hospitals & ClinicsCancer HospitalsResearch Institutes By Region North AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa More Trending Reports by Transparency Market Research - Oncology Nutrition Market (オンコロジー栄養市場)- The global oncology nutrition market is projected to advance at a CAGR of 6.2% from 2023 to 2031 Oncology Biosimilars Market (سوق البدائل الحيوية للأورام)- The global oncology biosimilars market is projected to expand at a CAGR of 27.5% during the forecast period from 2022 to 2025 About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Email: sales@transparencymarketresearch.com Follow Us: LinkedIn| Twitter| Blog | YouTube Market News and Data brought to you by Benzinga APIs

Benzinga

Mon, 2 Sept, 10:00 AM UTC

Tempus AI announces collaboration with Biontech (NASDAQ:BNTX)

Tempus AI (NASDAQ:TEM) announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX) which leverages Tempus' multimodal datasets in support of BioNTech's next-generation oncology pipeline. Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline. Source: Press Release More on BioNTech, Tempus AI, etc. Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy' BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise Moderna, Pfizer updated mRNA COVID vaccines authorized by FDA Partial hold on BioNTech, MediLink cancer drug lifted by FDA

Seeking Alpha

Wed, 4 Sept, 4:08 PM UTC

Similar products

BenevolentAI

BenevolentAI utilizes AI to accelerate drug discovery, enhancing scientific innovation and the likelihood of discovering successful drugs.

Contact for Pricing

Paige.AI

Paige is transforming the way pathologists work through a comprehensive digital pathology platform and generative AI applications.

Contact for Pricing

MDClone

MDClone is an AI-powered tool designed to democratize healthcare data, allowing organizations to utilize their in-house data to improve patient outcomes.

Freemium

Unlearn

Unlearn is a digital platform that uses artificial intelligence to create digital clones of human physiological responses, helping in drug development and clinical trials.

Contact for Pricing

PharmaTrace

PharmaTrace provides AI-powered digital solutions for chronic disease management, focusing on enhancing patient outcomes and preventing medical complications.

Contact for Pricing

Your one-stop AI hub

The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.

Creative and design

Tempus

Contact for Pricing

About Tempus

Related fields

Related News

Similar products

BenevolentAI

Paige.AI

MDClone

Unlearn

PharmaTrace

Your one-stop AI hub

The Outpost

Keep in touch